Navigation Links
Eisai USA Foundation to Donate $1 Million to the Conquer Cancer Foundation of the American Society of Clinical Oncology
Date:5/9/2013

WOODCLIFF LAKE, N.J., May 9, 2013 /PRNewswire/ -- Eisai USA Foundation Inc., the charitable arm of Eisai Inc., announces that it has pledged a $1 million donation to the Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO). The donation, which is being disbursed in four yearly installments of $250,000, will support the Conquer Cancer Foundation Mission Endowment, which was established to provide a long-term base of support to advance the Foundation's critical mission to improve the care and treatment of people living with cancer. The Mission Endowment focuses on funding research, professional education, patient education and information, international programs and initiatives that aim to improve access to and quality of care.

"Eisai USA Foundation is committed to advancing knowledge, research and patient care, particularly in oncology, a long-standing area of focus for Eisai," said Hideo Dan , executive vice president of the Eisai USA Foundation. "The work of the Conquer Cancer Foundation and ASCO aligns with our human health care (hhc) mission to help make a difference in the lives of patients. We are proud to support their vision of a world free from the fear of cancer."

"Eisai has been a dedicated supporter of the Conquer Cancer Foundation, providing critical funding for a range of initiatives over the years," said W. Charles Penley , MD, FASCO, Chair of the Conquer Cancer Foundation Board of Directors. "With Eisai's generous contribution to the Foundation's Mission Endowment, we can further expand our efforts to conquer cancer worldwide by funding breakthrough cancer research and sharing cutting-edge knowledge."

Eisai USA Foundation Inc.
The Eisai USA Foundation Inc. was established in 2008 as part of Eisai's commitment to be a responsible corporate citizen and contribute to the good of the society in which it does business. The Foundation focuses its charitable giving in four areas: health-related initiatives for patients and caregivers, disaster relief efforts, innovation in medical and pharmaceutical sciences, and community activities in the areas where Eisai's U.S. employees live and work.

Eisai Inc.
At Eisai Inc., human health care is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, manufacturing and marketing capabilities. Our key areas of commercial focus include oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). To learn more about Eisai Inc., please visit us at www.eisai.com/US

Eisai Inc. has affiliates that are part of a global product creation organization that includes R&D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania, as well as a global demand chain organization that includes manufacturing facilities in Maryland and North Carolina. Eisai's global areas of R&D focus include neuroscience; oncology; metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

Media Inquiries
Lisa Wolfe
201-746-2959
lisa_wolfe@eisai.com


'/>"/>
SOURCE Eisai Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Eisai To Sponsor 7th Annual National Walk For Epilepsy To Help Raise Epilepsy Awareness
2. Lynn Kramer, MD, Appointed Chief Clinical Officer of Eisai Product Creation Systems
3. FDA Grants Orphan Drug Status To Eisais Lenvatinib
4. Eisai Oncology to Present New Research on Eribulin at 35th Annual San Antonio Breast Cancer Symposium
5. Eisai USA Foundation to Donate $100,000 to the Hurricane Sandy New Jersey Relief Fund, $50,000 to the American Red Cross
6. Epilepsia Publishes Results From Two Studies Of Eisais Perampanel
7. Shaji Procida Appointed Vice President and Chief Financial Officer of Eisai Inc.
8. Eisai Oncology to Present New Research on Product Portfolio and Pipeline at ASCO Annual Meeting
9. National Patient Advocate Foundations Annual Capitol Hill Briefing Focuses on Patient Access Barriers to Life-Saving Medicines Placed on Specialty Tiers by Commercial Insurance Plans and Medicare
10. Epilepsy Foundation To Present Epilepsy Therapy Project Lifetime Accelerator Award To Henrik Klitgaard, Ph.D., Recognizing Contributions To New Therapies
11. Cardinal Health Foundation Invites Local Non-profit Organizations To Apply For Grants To Prevent Prescription Drug Abuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... LEXINGTON, Mass. , March 27, 2017   Pulmatrix, ... innovative inhaled therapies to address serious pulmonary diseases, today announced ... allergic fungal disease, cystic fibrosis and asthma to its ... Richard B. Moss , MD, ... former Director of the Cystic Fibrosis Center at Stanford University, ...
(Date:3/27/2017)... March 27, 2017 The global ... USD 16.0 billion by 2025, according to a new ... of chronic diseases is anticipated to be responsible for ... thereby widens the scope for growth during the forecast ... population, which is highly susceptible to chronic diseases, is ...
(Date:3/27/2017)... and BOSTON , ... a leading global pharmaceutical company and Paratek Pharmaceuticals, ... the development and commercialization of innovative therapies based ... 3 trials of sarecycline for the treatment of ... primary efficacy endpoints. Sarecycline is a once-daily, oral, ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of ... were things that his parents and teachers had asked of him that he had neglected ... going to defy the Almighty Creator. There were some who would have felt themselves to ...
(Date:3/27/2017)... ... 27, 2017 , ... New patients who have sleep apnea in ... or without a referral. Sleep apnea is often left untreated because patients are not ... and chronic snoring. , Dr. Braasch seeks to raise awareness of sleep apnea ...
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... White Plains, NY (PRWEB) , ... March 27, 2017 , ... ... honoring Root Canal Awareness Week by teaching their patients about the key role this ... canal therapy from an experienced endodontist. To better serve those who need a ...
(Date:3/27/2017)... ... 2017 , ... This is the second major release since ... 2014. It is the culmination of collaborative efforts by members of the OSEHRA ... Member Zato Health co-funded the ONC certification and provided key technical support throughout ...
Breaking Medicine News(10 mins):